{"filings":[{"id":3541196,"accession_number":"0001778922-26-000052","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-10-19T20:10:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"SpyGlass reports 4-year BIM-IOL data: 37% IOP cut, 86% off drops, no product-related AEs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim 4-year data in 21 evaluable patients: mean IOP fell 37% to 15.9 mmHg from 25.1 mmHg post-washout across 75/150/300 mcg dose groups.","86% (18 of 21) remained off all topical IOP-lowering drops; 90% maintained ≥20/25 best corrected distance visual acuity.","No product-related adverse events reported; FIH trial enrolled 23 patients, with 21 evaluable at 48 months (one moved abroad, one discontinued after cancer diagnosis).","BIM-IOL System is designed to deliver bimatoprost for up to 7 years in the FIH trial; Phase 3 version targets 3 years, with a 505(b)(2) NDA planned.","CEO Patrick Mooney cites approximately 1 million U.S. cataract procedures annually in glaucoma patients as the unmet need being targeted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3190398,"accession_number":"0001778922-26-000049","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-10-01T12:15:18+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"SpyGlass Pharma acquires AVS from Santen for $13M to secure IOL supply","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SpyGlass Pharma closed its acquisition of 100% of Advanced Vision Science (AVS) from Santen Holdings US on October 1, 2026, for a purchase price of $13,000,000 in cash.","AVS was SpyGlass Pharma's intraocular lens supplier and will continue to manufacture IOLs under the Eternity brand for Santen, which gets exclusive rights to sell those products in Japan.","At closing, AVS and Santen Pharmaceutical Co., Ltd. signed an Amended and Restated Supply and Distribution Agreement and cross licenses.","AVS will continue licensing its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for the enVista IOL line and manufacturing for other global IOL companies.","SpyGlass said the deal secures scalable commercial IOL manufacturing for its Phase 3 BIM-IOL System and may add toric and extended depth-of-focus premium lenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2106244,"accession_number":"0001778922-26-000044","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-08-06T20:16:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"SpyGlass Pharma Q2 net loss $19.9M; cash $234.2M; Phase 3 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.9M ($0.59 per share) vs $8.7M ($3.81) in Q2 2025.","Cash, cash equivalents and short-term investments of $234.2M expected to fund operations through 2028.","Enrollment in Phase 3 registrational trials of BIM-IOL System on track for completion in 2027.","BIM-DRS first-in-human trial expected to start in H2 2026.","Appointed Mike Pinder as VP Marketing; new CPT code for reimbursement pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442880,"accession_number":"0001778922-26-000033","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-05-14T20:15:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.","Cash & investments $251M as of Mar 31, 2026, funded through 2028 after $172.5M IPO in Feb 2026.","Phase 1/2 BIM-IOL 12-mo data: 98% drop-free, 34% mean IOP reduction from baseline at 78-mcg dose.","Phase 3 registrational trials SGP-005 and SGP-006 continue; enrollment completion expected in 2027.","Bimatoprost Drug Ring (BIM-DRS) first-in-human trial on track to start H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108400,"accession_number":"0001778922-26-000018","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SpyGlass Pharma reports FY2025 net loss $39.9M; positive Phase 1/2 data and $172.5M IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.6M in Q4 2025 ($5.72/sh) and $39.9M for FY2025 ($17.98/sh).","Cash $107.4M at Dec 2025; plus $172.5M IPO gross proceeds; runway through 2028.","Positive 12-month Phase 1/2 data: 97% of patients off IOP-lowering drops; mean IOP reduction 34-42%.","Phase 3 trials (SGP-005/SGP-006) enrolling; full enrollment expected 2027; BIM-DRS FIH trial in H2 2026.","Appointed Jean-Frédéric Viret as CFO and Habib Dable to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108399,"accession_number":"0001778922-26-000004","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SpyGlass Pharma reports positive 12-month Phase 1/2 results for BIM-IOL System; 97% off topical drops","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["97% of patients on BIM-IOL System were free from all topical IOP-lowering medications at 12 months.","Mean IOP reduction from baseline: 34% (78-mcg) and 42% (39-mcg) vs 35% for timolol control.","100% of BIM-IOL patients achieved BCDVA of 20/32 or better; mean BCDVA equivalent to 20/20.","Adverse event rates similar across groups (36.7%-43.5%); no serious ocular AEs observed.","Company is enrolling two identical registrational Phase 3 trials of the 78-mcg dose (initiated Jan 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108398,"accession_number":"0001628280-26-008073","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SpyGlass Pharma discloses FY2025 performance cash bonuses for named executive officers","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved FY2025 bonuses on Feb 12, 2026.","CEO Patrick Mooney: $215,088 bonus; total compensation $3,322,711.","President/CMO Malik Y. Kahook: $125,975 bonus; total $2,484,469.","Chief R&D Officer Chetan Pujara: $126,289 bonus; total $1,539,952.","Bonuses previously undisclosed in S-1; updated comp table filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108397,"accession_number":"0001628280-26-006460","cik":1778922,"company_name":"SpyGlass Pharma, Inc.","ticker":"SGP","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"SpyGlass Pharma closes IPO, raises $172.5M at $16.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO of 10,781,250 shares (incl. full exercise of underwriters' option for 1.4M additional shares) at $16.00/share.","Aggregate gross proceeds of $172.5 million before underwriting discounts and offering expenses.","Common stock began trading on Nasdaq Global Select Market under ticker SGP on February 6, 2026.","Habib Dable appointed to board as Class I director and to compensation committee; receives standard director compensation and option grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":678697065.9,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}